At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 48 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 17 Years and over
- Who
- All
- Number of participants
- 800
- Started
- 2024-10-30
- Last checked
- 2026-01
Plain English Summary
What is this study?
- • Testing a new treatment for dlbcl
- • Clinical study - 800 participants
- • LBCL is a cancer of the lymphatic system where B-cells (a type of white blood cell) experience uncontrolled growth
Who can take part?
- • Ages 17 Years and over
- • Diagnosed with dlbcl
Where?
- • Liverpool - The Clatterbridge Cancer Centre NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
LBCL is a cancer of the lymphatic system where B-cells (a type of white blood cell) experience uncontrolled growth. The standard treatment for LBCL is a combination of chemotherapy and immunotherapy, referred to as chemo-immunotherapy. Currently, the best results in the treatment of LBCL is with a chemo-immunotherapy combination called R-CHOP or Pola-R-CHP. Full doses of treatment are not suitable for elderly or frail patients due to potential to cause side effects and heart problems. Such patients either receive a reduced dose called mini-R-CHOP or receive alternatives (e.g. R-GCVP or R-CEOP). Additionally, some patients treated with R-CHOP or Pola-R-CHP may not respond or may respond initially before relapsing. For these patients, treatment is not standardised, and practice varies between hospitals. ALMANAC aims to collect data about the management and outcomes of patients with LBCL who are unsuitable for standard treatments because they are not well enough to tolerate the side effects or because they have not responded or relapsed following initial treatment. In doing so, it will guide research into LBCL leading to a better understanding of this condition and better outcomes.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 17 Years and over
- Who can join: All genders
Biomarkers mentioned
Treatment history
Treatments you must have had:
- ✓ of chemo-immunotherapy) including any line CAR-T therapy
What the study is looking for
- ✓Males and female subjects ≥16 years of age at the time of enrolment.
- ✓Ability to understand and sign written agreement to take part.
- ✓Previously untreated histologically proven Large B-cell non-Hodgkin's lymphoma (LBCL) according to the current World...
- ✓Cohort A:
- ✓De novo presentations of transformed indolent B-cell lymphomas.
Who cannot take part
- ✗Patients treated \>6 months prior to trial enrolment (Cohort B).
- ✗Patients eligible for full dose R-CHOP/Pola-R-CHP (Cohort A)
- ✗Patients with CNS lymphoma
- ✗Lymphoid proliferations and lymphomas associated with immune suppression and dysregulation. (e.g., Post-Transplant...
See the full criteria
Where Is This Study? (1 UK site)
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool L78YA, United Kingdom